Q32 Bio to Participate in the 25th Annual Needham Virtual Healthcare Conference
Q32 Bio to Participate in the 25th Annual Needham Virtual Healthcare Conference Q32 Bio to Participate in the 25th Annual Needham Virtual Healthcare Conference PR Newswire WALTHAM, Mass., April 8...
PR Newswire·18d ago
More News
Q32 Bio (NASDAQ:QTTB) Shares Up 4.6% - Should You Buy?
Q32 Bio (NASDAQ:QTTB) Trading Up 4.6% - Still a Buy...
MarketBeat·19d ago
Does Q32 Bio (QTTB) Have the Potential to Rally 97.66% as Wall Street Analysts Expect?
The consensus price target hints at a 97.7% upside potential for Q32 Bio (QTTB). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Zacks·27d ago
Best Momentum Stocks to Buy for March 27th
MGY, ESCA, and QTTB made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on March 27, 2026.
Zacks·1mo ago
New Strong Buy Stocks for March 27th
DNN, CM, MGY, QTTB and FLXS have been added to the Zacks Rank #1 (Strong Buy) List on March 27, 2026.
Zacks·1mo ago
Q32 Bio (QTTB) Upgraded to Strong Buy: Here's What You Should Know
Q32 Bio (QTTB) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Zacks·1mo ago
Best Momentum Stocks to Buy for March 19th
FIGS, QTTB and NESR made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on March 19, 2026.
Zacks·1mo ago
New Strong Buy Stocks for March 19th
FIGS, QTTB, ORN, FIX and PIPR have been added to the Zacks Rank #1 (Strong Buy) List on March 19, 2026.
Zacks·1mo ago
Best Momentum Stocks to Buy for March 13th
QTTB, DXPE and TTEC made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on March 13th, 2026.
Zacks·1mo ago
Wall Street Analysts See a 103.55% Upside in Q32 Bio (QTTB): Can the Stock Really Move This High?
The mean of analysts' price targets for Q32 Bio (QTTB) points to a 103.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.